Table 4 Results of main studies of conventional treatment in AL amyloidosis
From: AL Amyloidosis
Authors (references) | Regimen | Year of publication and N° of patients | Clonal response % (PR + CR) | CR% | TRM% | Median survival (years) |
|---|---|---|---|---|---|---|
Palladini et al. [61] | M-Dex | 2004/46 | 67 | 33 | 4 | 5,1 |
Jaccard et al. [21 | M-Dex | 2007/50 | 68 | 31 | 2 | 4,6 |
Wechalekar et al. [62] | CTD | 2007/75 | 74 | 21 | 4 | 3,4 |
Moreau et al. [63] | M-Dex -Lenalidomide | 2010/26 | 58 | 23 | 0 | 80% at 2 years |
Kastridis et al. [64] | Bortezomib + −dexamethasone | 2010/94 | 71 | 25 | 0 | 76% at 1 year |
Reece et al. [65] | Bortezomib | 2011/33 | 66 | 24 | 6 | 80% at 1 year |
Mickael et al. [66] | CyBorD | 2012/17 | 94 | 71 | 0 | 70% at 21 months |
Venner et al. [67] | CVD | 2012/43 | 81 | 41 | 0 | 97% at 2 years |